Beeline Medicines
Precision immunology spinout of 5 assets from Bristol-Myers Squibb (July 2025), backed by $300M from Bain Capital; not independently publicly traded
Privately held: no public share price
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | TLR7/8Small molecule | Systemic Lupus Erythematosus | |
| Phase 2 | TYK2Small molecule | Psoriasis | |
| Phase 1 | IL-2 receptor alpha (IL2RA)Biologic (subtype unspecified) | Atopic Dermatitis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (1)
April 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.